Health Tech Mohana Ravindranath and Katie Palmer STAT Plus: Elon Musk says Neuralink’s brain-machine interface could enter human studies next year
In the Lab Megan Molteni On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues
First Opinion Madhav Thambisetty Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage
Health Brian Melley — Associated Press A jury finds NCAA is not to blame in lawsuit over football player’s death after repeated head trauma
Health Megan Molteni Zapping the brain with electricity shown to boost older people’s short- and long-term memory
Health Tech Mario Aguilar STAT Plus: Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech
Health Elizabeth Cooney Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder
Health JoNel Aleccia — Kaiser Health News Worries about accuracy of widely used dementia test prompt training requirement
Health Lauren Gravitz Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s
The Pharmalot View Ed Silverman STAT Plus: Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer’s drug remarks
Biotech Matthew Herper and Allison DeAngelis STAT Plus: ‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug
First Opinion Earl Smith Victims of domestic abuse should get the same top-notch concussion care as athletes
Living With Isabella Cueto Lessons from a thriving physical therapist to a younger self just learning about multiple sclerosis
Biotech Allison DeAngelis STAT Plus: Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down
Exclusive Mario Aguilar STAT Plus: Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help
Health Andrew Joseph STAT Plus: An Alzheimer’s therapy scores winning results, but what could it mean for patients?
Health Jonathan Wosen Daily multivitamins improved the brain function of seniors in a trial — but plenty of questions remain
First Opinion Podcast Patrick Skerrett Listen: A doctor with ALS laments the slow pace for drug approval
Biotech Jason Mast STAT Plus: How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy
Health Tech Casey Ross STAT Plus: In early research, an AI model detects signs of Parkinson’s using breathing patterns
Biotech Adam Feuerstein STAT Plus: FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results
Biotech Adam Feuerstein STAT Plus: FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment
Health Tech Mario Aguilar STAT Plus: Startup gets green light to use Apple Watch to track Parkinson’s symptoms
First Opinion Cecille Joan Avila The often-overlooked connection between traumatic brain injury and domestic violence
In the Lab Jonathan Wosen The brain ‘learns’ to have seizures more efficiently and frequently over time, mouse study shows
First Opinion Bernard Zipprich Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?
The Pharmalot View Ed Silverman STAT Plus: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Health Tech Katie Palmer STAT Plus: With pharma still struggling in Alzheimer’s, health tech companies want a swing
In the Lab Meghana Keshavan With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption